BMJ Acceptance Rate

BMJ's acceptance rate has remained consistently low across the past decade, reflecting the journal's sustained editorial selectivity as it grew in impact factor.

Key trend: BMJ's acceptance rate has held remarkably stable at approximately 7% even as the IF rose from 17.4 to a peak of 93.3 in 2022, then settled at 42.7 in 2024. The IF swings were driven largely by COVID-era citation patterns, not changes in editorial selectivity. The desk rejection rate has climbed from roughly 75% in 2015 to 80-85% today, meaning a larger share of the ~7% acceptance now comes from papers that survive a stricter initial editorial screen.

The practical implication: submitting in 2026 is no easier than 2015 despite the dramatically higher IF. The acceptance rate is stable; the IF growth reflects the journal's growing citation reach, not loosened standards.

BMJ's desk rejection rate (80-85%) is comparable to the Lancet. The editorial filter has a specific population health emphasis. The editors ask: does this finding matter at a population level, not just for individual patients?

A treatment that works in a clinical trial is interesting. A treatment that changes population health outcomes is BMJ material. This distinction catches many strong clinical papers that have individual-level significance without population-level implications.

BMJ's open peer review means reviewer names are published alongside accepted papers. This creates a different review culture:

• Reviews tend to be more constructive (reviewers sign their work)
• Unreasonable demands are rare (they become part of the public record)
• Some reviewers decline because they don't want their identity attached to the review
• Finding reviewers can take longer than at anonymous journals

For authors, this means the feedback you receive is usually more carefully considered. The trade-off is that the reviewer recruitment phase can be slower.

Submit if:

• the clinical finding has population health relevance (not just individual patient impact)
• you're comfortable with open peer review (reviewer names will be public)
• no APC is important for your funding situation
• the evidence level is strong enough for the BMJ's statistical scrutiny

Think twice if:

• the clinical importance is individual-level rather than population-level
• you prefer anonymous peer review
• NEJM or the Lancet is a more natural editorial fit for the clinical question
• the finding is specialty-specific (specialty journals are a better home)

A BMJ submission readiness check can help assess whether the population health framing meets BMJ's editorial expectations.

In our pre-submission review work evaluating manuscripts targeting BMJ, three patterns generate the most consistent desk rejections. Each is grounded in the journal's own published submission criteria and editorial commentary.

Study findings that are clinically valid but not population-relevant. BMJ's editorial standards require that research "has the potential to change practice or illuminate an important medical or scientific question." The failure pattern is a clean clinical study where the finding matters to individual patient management but has no clear population health implication. A trial showing that drug A is 15% more effective than drug B for condition X is clinically useful; BMJ wants to know whether this changes how healthcare systems should allocate resources or whether screening policies should shift. This population-level framing is not just presentation polish: it is an editorial requirement that many strong clinical papers fail to meet.

Narrow specialty scope without general medical applicability. BMJ's own guidance states that "only research with international general interest" is considered for the flagship journal. The most direct desk rejection trigger is a paper whose introduction, methods, and discussion assume subspecialty familiarity. A paper on a highly specific surgical technique, a rare hematological disorder, or a disease with narrow geographic prevalence will be directed to a BMJ specialty journal regardless of methodological quality. The test is simple: would a well-read general practitioner in a different country find this clinically relevant to their practice? If the answer requires substantial specialty context to be yes, the submission belongs elsewhere.

Statistical analysis that does not meet BMJ's rigor threshold. BMJ employs statistical editors who review manuscripts before peer review. Papers with unadjusted analyses where confounding is plausible, with p-values reported without effect sizes and confidence intervals, or with underpowered samples for the claimed finding, are returned before external review. The journal's statistical guidelines require that "all statistical analyses include effect sizes with 95% confidence intervals." Papers in epidemiology must include multivariable adjustment and clearly specify model covariates. Presenting raw odds ratios without adjustment, or reporting significance without absolute risk differences, is the kind of statistical incompleteness that BMJ's statistical desk catches before the paper reaches a clinical reviewer. A BMJ statistical rigor and scope check can assess whether the statistical package meets BMJ's threshold before submission.

The acceptance rate at BMJ is only one dimension of selectivity. What matters more is where in the process papers are filtered. Most rejections at selective journals happen at the desk - the editor reads the abstract, cover letter, and first few paragraphs and decides whether to send the paper for external review. Papers that make it past the desk have substantially better odds.

For authors, this means the real question is not "what percentage of papers get accepted?" but "will my paper survive the desk screen?" The desk screen is about scope fit, novelty signal, and evidence maturity - not about statistical odds.

If you are considering BMJ, these specific steps improve your chances:

• Lead with the advance, not the method. The first paragraph of your abstract should state what changed in the field, not how you ran the experiment.

• Match the journal's scope precisely. Read the last 3 issues. If your paper's topic doesn't appear, the desk rejection risk is high.

• Include a cover letter that addresses fit. Name the specific reason this paper belongs at BMJ rather than a competitor.

• Ensure the data package is complete. Missing controls, weak statistics, or incomplete characterization are common desk-rejection triggers.

• Check formatting requirements. Trivial formatting errors signal carelessness to editors.

For BMJ, authors should expect:

These are approximate ranges. Actual timelines vary by manuscript complexity, reviewer availability, and whether revisions are needed.

The acceptance rate for BMJ does not distinguish between desk rejections and post-review rejections. A paper desk-rejected in 2 weeks and a paper rejected after 4 months of review both count the same. The rate also does not reveal how acceptance varies by article type, geographic origin, or research area within the journal's scope.

Acceptance rates cannot predict your individual odds. A strong paper with clear scope fit, complete data, and solid methodology has substantially better odds than the headline number suggests. A weak paper with methodology gaps will be rejected regardless of the journal's overall rate.

Before submitting, a BMJ scope fit and desk-rejection risk check assesses desk-reject risk for your specific manuscript.